besifloxacin

besifloxacin

(be-si-flox-a-sin) ,

Besivance

(trade name)

Classification

Therapeutic: anti infectives
Pharmacologic: fluoroquinolones
Pregnancy Category: C

Indications

Treatment of bacterial conjunctivitis.

Action

Inhibits bacterial DNA synthesis by inhibiting DNA gyrase.

Therapeutic effects

Death of susceptible bacteria with decreased symptoms and sequelae of bacterial conjunctivitis.
Active against CDC coryneform group G, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus lugdunensis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae and Streptococcus salivarius.

Pharmacokinetics

Absorption: Minimal absorption follows ophthalmic use.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: 7 hr.

Time/action profile

ROUTEONSETPEAKDURATION
Ophthunknownunknown6–12 hr

Contraindications/Precautions

Contraindicated in: Contact lens use.
Use Cautiously in: Obstetric: Use during pregnancy only if potential benefit justifies potential risk to fetus; Lactation: Use cautiously during lactation; Pediatric: Safe use in children <1 yr not established.

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • conjunctival redness (most frequent)
  • blurred vision
  • eye irritation
  • eye pain,
  • eye pruritus.

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Ophthalmic (Adults and Children ≥1 yr) One drop in affected eye(s) three times daily (4–12 h apart) for 7 days.

Availability

Ophthalmic suspension: 0.6% 5 mL in 7.5 mL bottle

Nursing implications

Nursing assessment

  • Assess eye for signs of infection (swelling, redness, pain, discharge) prior to and periodically during therapy.

Potential Nursing Diagnoses

Risk for infection (Indications)

Implementation

  • Ophthalmic: Invert closed bottle and shake once before use. Remove cap with bottle still inverted. Tilt head back and, with bottle inverted, gently squeeze bottle to instill 1 drop in affected eye 3 times daily (4–12 hrs apart) for 7 days.

Patient/Family Teaching

  • Instruct patient to use besifloxacin as directed, even if feeling better. Do not skip doses or stop therapy early; may lead to decreased effectiveness and resistant infections. Avoid touching applicator to eye, finger, or other areas; may contaminate. Wash hands prior to instillation.
  • Caution patient to avoid wearing contact lenses during therapy.
  • Advise patient to discontinue immediately and notify health care professional if signs or rash or allergic reaction (hives, difficulty breathing, swelling of throat) occur.

Evaluation/Desired Outcomes

  • Resolution of signs and symptoms of infection.
References in periodicals archive ?
Bacterial Conjunctivitis Drugs Market, by Drug Class Fluoroquinolones Ciprofloxacin Ofloxacin Levofloxacin Moxifloxacin Gatifloxacin Besifloxacin Aminoglycosides Tobramycin Gentamycin Macrolides Erythromycin Azithromycin Others U.
15) However, studies supporting the use of antibiotics in secondary care involving selected patients, such as polymixin-bacitracin, azithromycin, besifloxacin, moxifloxacin, ciprofloxacin and norfloxacin, produce a statistically significant and faster improvement in clinical resolution or bacterial eradication compared to placebo.
Efficacy and safety of besifloxacin ophthalmic suspension 0.
Therapeutic use: Besifloxacin (5, 6) is an ophthalmic antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of Centers for Disease Control and Prevention coryneform group G, Corynebacterium pseudodiphtheriticum, Corynebacterium striatum, Haemophilus influenzae, Moraxella lacunata, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus lugdunensis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, and Streptococcus salivarius.
Bepotastine (Bepreve; C), an antihistamine, and besifloxacin (Besivance; C), a quinolone antibiotic, are new ophthalmic products.
Bepotastine, besifloxacin, ecallantide, golimumab, ofatumumab, prasugrel, telavancin, and vigabatrin appear to be compatible with breastfeeding, but there are human data only for vigabatrin.
A Food and Drug Administration advisory panel voted 9-0 that an ophthalmic formulation of besifloxacin, a new fluoroquinolone antibiotic, should be approved for treating bacterial conjunctivitis in people aged 1 year and older.
At a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee, panel members agreed that the data presented from three studies provided adequate evidence that besifloxacin hydrochloride ophthalmic suspension (0.
The trials compared besifloxacin with a vehicle suspension in two studies and with moxifloxacin HCl ophthalmic solution 0.
In the two studies that compared besifloxacin with the vehicle, the rates of resolution in clinical symptoms after 4-6 days were significantly greater among those who were treated with besifloxacin.
Multidrug-Resistance in Bacterial Conjunctivitis Studies with Besifloxacin Ophthalmic Suspension, 0.
Topical ophthalmic besifloxacin offers physicians the opportunity to provide patients with an anti-infective that treats a broad range of bacterial ocular pathogens," said Marguerite McDonald, MD, FACS, Clinical Professor of Ophthalmology at NYU School of Medicine, New York, New York.